MICRO-BRAIN 2024: Study on Pediatric Brain Tumors

Condition(s) studied

Investigational drug(s) / intervention(s)

Biological samples: Analysis of fungal and bacterial genomic DNA from fecal samples, rectal swabs, and tumor biopsy

Fecal samples: Analysis of fungal and bacterial genomic DNA from fecal samples

Study summary

In recent years, there has been growing interest in the human gut microbiota, whose health is characterised by high microbial diversity. Through the gut-brain axis, the microbiota influences the homeostasis of the central nervous system by regulating neurological, immune and epigenetic functions. Intestinal dysbiosis is associated with various neurological and oncological diseases, including paediatric diseases and colorectal cancer. Recent studies highlight a significant link between microbiota and brain tumours: cancer patients show reduced microbial richness and altered bacterial composition. In addition, an intratumoural microbial population has been identified that can influence tumour initiation, progression and response to therapies by modulating tumour cells and the immune system. The aim of this study is to analyse stool samples to study the microbiota in children suspected CNS brain tumor as there are currently no studies of this kind reported in the literature to assess whether microbial changes can be detected at diagnosis, can be found during the course of the disease or are associated with tumour progression.

Eligibility

Primary outcome measure(s)

• Change in the composition of the microbiota — At enrollment; 6 months post-enrollment; on the date of the first documented progression assessed up to 36 months

Trial sites (1)

More Meyer Children's Hospital IRCCS trials in Italy

Other trials for the same condition